CA2492331A1 - Use of convertase inhibitors in the treatment of fibrosis and scarring - Google Patents

Use of convertase inhibitors in the treatment of fibrosis and scarring Download PDF

Info

Publication number
CA2492331A1
CA2492331A1 CA002492331A CA2492331A CA2492331A1 CA 2492331 A1 CA2492331 A1 CA 2492331A1 CA 002492331 A CA002492331 A CA 002492331A CA 2492331 A CA2492331 A CA 2492331A CA 2492331 A1 CA2492331 A1 CA 2492331A1
Authority
CA
Canada
Prior art keywords
tgf
inhibitor
scarring
use according
convertase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002492331A
Other languages
English (en)
French (fr)
Inventor
Mark William James Ferguson
Georg Brunner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of CA2492331A1 publication Critical patent/CA2492331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002492331A 2002-07-24 2003-07-23 Use of convertase inhibitors in the treatment of fibrosis and scarring Abandoned CA2492331A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217136.1 2002-07-24
GBGB0217136.1A GB0217136D0 (en) 2002-07-24 2002-07-24 Wound healing & treatment of fibrosis
PCT/GB2003/003159 WO2004009113A1 (en) 2002-07-24 2003-07-23 Use of convertase inhibitors in the treatment of fibrosis and scarring

Publications (1)

Publication Number Publication Date
CA2492331A1 true CA2492331A1 (en) 2004-01-29

Family

ID=9941004

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002492331A Abandoned CA2492331A1 (en) 2002-07-24 2003-07-23 Use of convertase inhibitors in the treatment of fibrosis and scarring

Country Status (11)

Country Link
US (2) US7700562B2 (da)
EP (1) EP1556080B1 (da)
JP (1) JP4630661B2 (da)
AT (1) ATE486609T1 (da)
AU (1) AU2003254473B2 (da)
CA (1) CA2492331A1 (da)
DE (1) DE60334830D1 (da)
DK (1) DK1556080T3 (da)
ES (1) ES2355094T3 (da)
GB (1) GB0217136D0 (da)
WO (1) WO2004009113A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414423A (pt) * 2003-09-16 2006-11-14 Pharmacia Corp inibidores de pace4, suas composições farmacêuticas e respectivos usos
WO2005037150A1 (en) * 2003-10-16 2005-04-28 Osteotech, Inc. System and method for flexible correction of bony motion segment
WO2008066707A2 (en) * 2006-11-29 2008-06-05 Dana-Farber Cancer Institute Targeting prohormone convertase enzymes to suppress pomc-msh processing to induce skin lightening
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
US8658591B2 (en) 2008-07-11 2014-02-25 Robert Day Multi-LEU peptides and analogues thereof as selective PACE4 inhibitors and effective antiproliferative agents
CA2819810A1 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
JP6472608B2 (ja) 2014-05-21 2019-02-20 ソマール株式会社 Ｎ−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム
WO2017141032A1 (en) * 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356595A1 (en) 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Novel peptidase inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
GB9314350D0 (en) 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5972335A (en) 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
WO2000040227A2 (en) * 1999-01-05 2000-07-13 University Of Utah Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6262020B1 (en) * 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
CA2312109A1 (en) * 2000-06-23 2001-12-23 Universite De Sherbrooke Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides

Also Published As

Publication number Publication date
JP4630661B2 (ja) 2011-02-09
WO2004009113A1 (en) 2004-01-29
JP2005535674A (ja) 2005-11-24
AU2003254473B2 (en) 2008-05-01
EP1556080B1 (en) 2010-11-03
HK1073438A1 (en) 2005-10-07
GB0217136D0 (en) 2002-09-04
DE60334830D1 (de) 2010-12-16
EP1556080A1 (en) 2005-07-27
ES2355094T3 (es) 2011-03-22
ATE486609T1 (de) 2010-11-15
US20110059896A1 (en) 2011-03-10
AU2003254473A1 (en) 2004-02-09
US20060052309A1 (en) 2006-03-09
DK1556080T3 (da) 2011-01-31
US7700562B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
US20110059896A1 (en) Use of furin convertase inhibitors in the treatment of fibrosis and scarring
Tao et al. Platelet-activating factor induces the expression of metalloproteinases-1 and-9, but not-2 or-3, in the corneal epithelium.
EP1009425B1 (en) Use of Latency Associated Peptide for the manufacture of a medicament for increasing wound healing.
WO1998036061A2 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
US20140287985A1 (en) Novel uses of elafin
EP0941108B1 (en) Wound healing and treatment of fibrosis
EP2298336A9 (en) Promotion of epithelial regeneration
EP1152757B1 (en) Mmp inhibitors in connective tissue softening
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
JP2003530309A (ja) 増殖性皮膚疾患又は増殖性眼疾患を治療するリボザイム療法
HK1073438B (en) Furin inhibitors for use in the treatment of fibrosis and scarring
JP2026504432A (ja) 哺乳動物における医療用途のための組織メタロプロテアーゼ阻害物質タンパク質をコードするオリゴヌクレオチド
HK1025732B (en) Wound healing and treatment of fibrosis
HK1037960B (en) Mmp inhibitors in connective tissue softening
HK1025504B (en) Use of latency associated peptide for the manufacture of a medicament for increasing wound healing

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued